In 2022, my wife and I were ready to take the next step to start a family. Like many people, I began with a simple step: checking in with a doctor to make sure everything was on track with my health. I never imagined that visit would uncover a diagnosis that could take both my future and my life. And I certainly didn’t expect that my survival would depend on access to a clinical trial.
Three years ago, I was diagnosed with Lynch Syndrome, an inherited genetic condition that significantly increases the risk of colorectal and other cancers. Shortly after, a colonoscopy revealed a mass in my rectum. Because of a specific biomarker linked to my condition, I qualified for a groundbreaking clinical trial.
That trial changed everything.
Instead of enduring chemotherapy, radiation and invasive surgery, I received an innovative therapy. Within three months, the mass was undetectable. What could have been a devastating, life-altering medical journey became something entirely different.
Stories like mine are only possible because clinical trials exist, and because the system that supports them works.
Today, that system is at risk.
California lawmakers are considering Assembly Bill 1776, legislation intended to strengthen antitrust enforcement. But as written, the bill could unintentionally disrupt the cross-sector collaborations that make clinical trials possible. It expands the state’s authority to challenge business practices deemed “anticompetitive,” creating new uncertainty for the partnerships between researchers, hospitals and innovators that drive medical progress.
In biomedical research, collaboration is foundational, not optional. The same relationships that might raise concerns in other industries are often essential to developing new treatments and bringing them to patients through clinical trials.
California leads the world in clinical research, with thousands of trials actively recruiting patients across the state. These studies are not theoretical – they are where new therapies are tested, refined and delivered to people who need them most like me.
If AB 1776 disrupts the clinical trial pipeline, the consequences will be profound. Fewer clinical trials, slower research, and reduced access to cutting-edge treatments could become the new reality. For those of us facing rare or life-threatening conditions, time is not a luxury. Treatment delays can mean the difference between life and death.
I am one of the fortunate ones. My condition was caught early. A clinical trial was available. The treatment worked.
But not everyone will be so lucky if policies like AB 1776 unintentionally undermine the very system that made my recovery possible. I urge California lawmakers to reject AB 1776 and protect the clinical trials that save lives every day.
Jessica Acosta is a patient advocate who lives in San Diego.
Hence then, the article about opinion clinical trials saved my life california shouldn t put them at risk was published today ( ) and is available on Times of San Diego ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Opinion: Clinical trials saved my life — California shouldn’t put them at risk )
Also on site :
- Britney Spears Spends Time With Diane Warren and Molly Shannon After DUI
- 'You should resign': Mamata hits out at PM Modi's silence on Pakistan's threat to strike Kolkata
- IAEA: Continued military activity near Bushehr Plant could cause radiological accident